We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You canĀ read more about our cookies before you choose.
Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)
Arsenic trioxide in combination with all-trans retinoic acid (ATRA) is recommended to be available as a routine commissioning treatment option for high-risk acute promyelocytic leukaemia (APML) within the criteria set out in this document.